SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

SpaceXs agreement to acquire low-band spectrum for Starlink Mobile triggered a sharp selloff in T-Mobile and other wireless carriers as investors weighed the prospect of a new competitor. Traders are divided between seeing a meaningful long-term threat to carrier growth and viewing the decline as an overreaction, since building a competitive network would require substantial infrastructure and time.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Anticipation around Patrick Soon-Shiongs upcoming oncology symposium fireside chat is driving attention, with traders hoping for concrete trial updates and other company news. Some also link ImmunityBios cancer-vaccine research to a broader NIH initiative, though claims of an imminent government partnership or deal remain speculation; bullish short-squeeze chatter is prominent as well.

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

AT&T Inc

AT&T shares sold off amid concerns that SpaceXs spectrum acquisition could support a Starlink Mobile service competing with established wireless carriers. Traders debated whether the move signals a meaningful long-term threat or an overreaction, noting the time and infrastructure needed to build a rival network while some viewed the drop as a buying opportunity tied to AT&Ts established business and dividend.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JASMYs price action and possible breakout are drawing attention, with traders split between dip-buying and warnings that rallies may fade. Bulls point to new JasmyChain activity and ecosystem partnerships as signs of potential utility, while skeptics argue meaningful adoption remains unproven and cite weak performance and exchange delistings.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

NVAX rose in sympathy with a broader vaccine-stock rally after a report on an NIH push to accelerate personalized cancer vaccines; traders also speculated that Novavaxs Matrix-M platform could benefit, though the company has no cancer-vaccine program. Short-squeeze claims and hopes around Sanofis COVID-flu trial also circulated, but some traders viewed the move as sector-driven and cautioned that gains could fade.

Arista Networks, Inc. engages in the development, marketing, and sale of cloud networking solutions. Its solutions include EOS, a set of network applications, and Gigabit Ethernet switching and routing platforms. Its product categories include core, cognitive adjacencies, and cognitive networks. The company was founded by Andreas Bechtolsheim, David Cheriton, and Kenneth Duda in November 2004 and is headquartered in Santa Clara, CA.

Arista Networks Inc

Arista shares are drawing attention after breaking to fresh 52-week and all-time highs, with traders pointing to strong momentum and optimism about AI data-center networking demand. The community is largely bullish, though some caution about insider selling, valuation, and the risk of a pullback.

Zoracles

A sharp, high-volume move in ZORA has sparked breakout and short-squeeze speculation, while skeptics warn that the volatile rallies may be short-lived. Some traders point to Zoras expansion into Solana-based attention markets, though they question whether that product creates value for ZORA token holders.

Redwire Corp. engages in the development and provision of space and defense technologies and mission-critical solutions for government, commercial, and civil customers. Its offerings include spacecraft platforms, space infrastructure, avionics, sensors and payloads, power generation systems, radio frequency systems, microgravity research and manufacturing technologies, autonomous systems, optical sensors, and digital engineering solutions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwires shares are drawing attention for their weak, volatile trading despite contract and partnership headlines, including follow-on solar-array work for Axiom Space. Traders debate whether ATM share sales and broader small-cap weakness are weighing on the stock, while bulls point to its growing contract pipeline and view the pullback as a buying opportunity.

Snowflake, Inc. engages in the provision of cloud data warehousing software. The firm offers Data Cloud, an ecosystem where Snowflake customers, partners, data providers, and data consumers can break down data silos and derive value from data. Its platform supports a range of use cases including data warehousing, data lakes, data engineering, data science, data application development, and data sharing. The cloud-native architecture consists of layers across storage, compute, and cloud services. The storage layer ingests structured and semi-structured data to create a unified data record. The compute layer provides dedicated resources to enable users to access common data sets for many use cases without latency. The cloud services layer optimizes each use case's performance requirements with no administration. The company was founded by Marcin Zukowski, Thierry Cruanes, and Benoit Dageville on July 23, 2012 and is headquartered in Menlo Park, CA.

Snowflake Inc

Snowflakes Agentic Marketplace Discovery launch and renewed enthusiasm for AI-focused software are driving attention, with traders framing the move as a breakout. Bulls see AI adoption supporting growth, while skeptics point to the stocks valuation and lack of GAAP profitability.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs rally to fresh highs is drawing attention after Goldman Sachs upgraded the stock, citing sovereign AI demand and growth opportunities in customized software. Bulls are celebrating the momentum and speculating about a squeeze, while skeptics argue the valuation is stretched and the run may be due for a pullback.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Here's Why Exelixis (EXEL) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Exelixis (EXEL) is a Top-Ranked Growth Stock: Should You Buy?

Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans?

Exelixis faces a three-month FDA review delay for zanzalintinib, pushing the potential CRC decision to March 2027.

Here's Why Exelixis (EXEL) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Alpha Teknova (TKNO) Moves 7.1% Higher: Will This Strength Last?

Alpha Teknova (TKNO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Exelixis (EXEL) is a Strong Growth Stock

EXEL Stock Slides After FDA Adds Three Months To Cancer Drug Review — William Blair Sees More Swings In Near Term

Equity

The FDA told Exelixis on Thursday that it had extended the review of a new drug application for zanzalintinib plus Roche’s Tecentriq in patients whose colorectal cancer has spread. 

Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In

FDA extends Exelixis NDA review for zanzalintinib to March 2027. Analyst evaluates stock volatility and revenue outlook.read more...

Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue?

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Exelixis, Inc. is an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Exelixis Inc

Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$59.86
Prev Close	$59.02
Open	$59.00
Dividend Yield	0.00%
50-Day Moving Average	$56.14
Beta	0.49
Avg. Volume	2.22M
PE Ratio	18.80

52-Week High	$61.14
52-Week Low	$33.76
Market Capitalization	$14.62B
EPS (Annual)	$2.78
Price to Book	8.08
Revenue Per Employee	$2.15M

Feed

News

Sentiment

Earnings

Fundamentals

Info

EXEL Fundamentals